ClaimsFiler Alerts Investors on Soleno Therapeutics Securities Class Action
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy SLNO?
Source: Globenewswire
- Filing Deadline: ClaimsFiler reminds investors of Soleno Therapeutics that lead plaintiff applications must be submitted by May 5, 2026, for shares purchased between March 26 and November 4, 2025, highlighting the legal urgency faced by investors.
- Legal Allegations Overview: Soleno and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, particularly regarding undisclosed safety concerns related to the DCCR clinical trial, which could undermine investor confidence in the company’s future.
- Product Safety Risks: The lawsuit highlights that DCCR, the only commercial product for treating Prader-Willi syndrome, has undisclosed safety risks, including excessive fluid retention among trial participants, potentially affecting its market acceptance and commercial viability.
- Potential Consequences: The questioning of DCCR's commercial viability could lead to increased patient discontinuation rates, prescriber reluctance, adverse regulatory actions, and reputational damage, posing significant financial risks to investors in Soleno.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 52.570
Low
75.00
Averages
110.50
High
125.00
Current: 52.570
Low
75.00
Averages
110.50
High
125.00
About SLNO
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Soleno Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Background: Hagens Berman reminds investors that Soleno Therapeutics (NASDAQ: SLNO) is facing a class action lawsuit for failing to disclose safety risks, urging investors to submit claims by May 5, 2026, for stock purchases made between March 26 and November 4, 2025.
- Safety Risk Allegations: The lawsuit alleges that Soleno concealed significant safety concerns regarding its flagship product VYKAT™ XR, including risks of fluid retention and heart failure in children, which could severely impact the company's reputation and future sales.
- Data Integrity Issues: Reports indicate that Soleno's Phase 3 clinical trials relied on a controversial physician whose data showed inconsistencies, potentially eroding investor trust in the company's data and affecting stock performance.
- Stock Price Volatility: On November 4, 2025, Soleno admitted to disruptions in the launch of DCCR, leading to a 27% drop in stock price in a single day, reflecting a severe lack of market confidence in the company's future prospects and potentially hindering future financing capabilities.
See More
Soleno Therapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Soleno Therapeutics (NASDAQ:SLNO), alleging securities fraud and other unlawful business practices, with investors advised to apply as Lead Plaintiff by May 5, 2026.
- Stock Price Plunge: Following a report by Scorpion Capital on August 15, 2025, which labeled Soleno's sole product DCCR as overpriced and potentially unsafe for children, the stock price fell by $5.73, a decrease of 7.41%.
- Patient Death Incident: On September 10, 2025, Soleno disclosed that a patient died after taking DCCR, leading to a stock price drop of $13.49, or 19.21%, over the next two trading sessions.
- Adverse Reaction Disclosure: During a quarterly earnings call on November 4, 2025, Soleno revealed an 8% discontinuation rate for DCCR due to adverse effects, with the CEO stating that the Scorpion report disrupted the product's launch trajectory, causing a stock price decline of $16.98, or 26.59%.
See More
ClaimsFiler Alerts Investors on Soleno Therapeutics Securities Class Action
- Filing Deadline: ClaimsFiler reminds investors of Soleno Therapeutics that lead plaintiff applications must be submitted by May 5, 2026, for shares purchased between March 26 and November 4, 2025, highlighting the legal urgency faced by investors.
- Legal Allegations Overview: Soleno and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, particularly regarding undisclosed safety concerns related to the DCCR clinical trial, which could undermine investor confidence in the company’s future.
- Product Safety Risks: The lawsuit highlights that DCCR, the only commercial product for treating Prader-Willi syndrome, has undisclosed safety risks, including excessive fluid retention among trial participants, potentially affecting its market acceptance and commercial viability.
- Potential Consequences: The questioning of DCCR's commercial viability could lead to increased patient discontinuation rates, prescriber reluctance, adverse regulatory actions, and reputational damage, posing significant financial risks to investors in Soleno.
See More
Soleno Therapeutics Shareholder Class Action Filed
- Class Action Initiation: A shareholder has filed a securities class action lawsuit against Soleno Therapeutics (NASDAQ: SLNO) on behalf of investors who purchased shares between March 26, 2025, and August 4, 2025, alleging misrepresentations regarding the company's Phase 3 clinical trial for DCCR, which may have led to investor losses.
- Legal Procedure Details: Investors wishing to serve as lead plaintiffs must file necessary documents by May 5, 2026, with the lead plaintiff representing other shareholders in directing the litigation, although non-lead plaintiffs can still share in any recovery.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal’s “Plaintiffs’ Hot List” for its success in litigating hundreds of class actions, showcasing its strong reputation in securities litigation.
- Transparent Fee Structure: All representation in this lawsuit is on a contingency fee basis, meaning shareholders incur no fees or expenses, which reduces the financial burden on investors and encourages more affected shareholders to participate.
See More
Multiple Companies Face Class Action Lawsuits
- Eos Energy Lawsuit: Eos Energy Enterprises is facing allegations for failing to meet production and capacity utilization targets from November 2025 to February 2026, which could severely undermine investor confidence and negatively impact its stock performance.
- Soleno Therapeutics Risks: Soleno Therapeutics is accused of concealing safety concerns in its DCCR clinical trials, potentially exposing patients to greater risks, which may adversely affect product acceptance and commercial viability, leading to potential investor losses.
- Nektar Therapeutics Trial Issues: Nektar Therapeutics is under scrutiny for not adhering to applicable standards in its REZOLVE-AA trial, which could compromise the integrity of trial results and affect future R&D and market strategies, creating uncertainty for shareholders.
- Driven Brands Financial Errors: Driven Brands is accused of financial reporting errors from 2023 to 2026, resulting in misstatements of cash flows and revenues, which could negatively impact its financial health and investor confidence.
See More
Soleno Therapeutics Securities Class Action Reminder
- Lawsuit Background: Hagens Berman reminds investors of the pending securities class action against Soleno Therapeutics (NASDAQ:SLNO), with a lead plaintiff deadline of May 5, 2026, for those who purchased shares between March 26 and November 4, 2025.
- Safety Risk Allegations: The lawsuit alleges that Soleno misrepresented the safety and commercial viability of its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, leading to significant investor losses due to concealed risks.
- Stock Price Plunge: On November 4, 2025, Soleno reported Q3 results, admitting disruptions in DCCR's launch trajectory, resulting in a 27% stock price drop in one day, indicating severe market disappointment regarding the company's future.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to consider the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, thereby aiding the investigation into Soleno's practices.
See More
Soleno Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Background: Hagens Berman reminds investors that Soleno Therapeutics (NASDAQ: SLNO) is facing a class action lawsuit for failing to disclose safety risks, urging investors to submit claims by May 5, 2026, for stock purchases made between March 26 and November 4, 2025.
- Safety Risk Allegations: The lawsuit alleges that Soleno concealed significant safety concerns regarding its flagship product VYKAT™ XR, including risks of fluid retention and heart failure in children, which could severely impact the company's reputation and future sales.
- Data Integrity Issues: Reports indicate that Soleno's Phase 3 clinical trials relied on a controversial physician whose data showed inconsistencies, potentially eroding investor trust in the company's data and affecting stock performance.
- Stock Price Volatility: On November 4, 2025, Soleno admitted to disruptions in the launch of DCCR, leading to a 27% drop in stock price in a single day, reflecting a severe lack of market confidence in the company's future prospects and potentially hindering future financing capabilities.
See More
Soleno Therapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Soleno Therapeutics (NASDAQ:SLNO), alleging securities fraud and other unlawful business practices, with investors advised to apply as Lead Plaintiff by May 5, 2026.
- Stock Price Plunge: Following a report by Scorpion Capital on August 15, 2025, which labeled Soleno's sole product DCCR as overpriced and potentially unsafe for children, the stock price fell by $5.73, a decrease of 7.41%.
- Patient Death Incident: On September 10, 2025, Soleno disclosed that a patient died after taking DCCR, leading to a stock price drop of $13.49, or 19.21%, over the next two trading sessions.
- Adverse Reaction Disclosure: During a quarterly earnings call on November 4, 2025, Soleno revealed an 8% discontinuation rate for DCCR due to adverse effects, with the CEO stating that the Scorpion report disrupted the product's launch trajectory, causing a stock price decline of $16.98, or 26.59%.
See More
ClaimsFiler Alerts Investors on Soleno Therapeutics Securities Class Action
- Filing Deadline: ClaimsFiler reminds investors of Soleno Therapeutics that lead plaintiff applications must be submitted by May 5, 2026, for shares purchased between March 26 and November 4, 2025, highlighting the legal urgency faced by investors.
- Legal Allegations Overview: Soleno and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, particularly regarding undisclosed safety concerns related to the DCCR clinical trial, which could undermine investor confidence in the company’s future.
- Product Safety Risks: The lawsuit highlights that DCCR, the only commercial product for treating Prader-Willi syndrome, has undisclosed safety risks, including excessive fluid retention among trial participants, potentially affecting its market acceptance and commercial viability.
- Potential Consequences: The questioning of DCCR's commercial viability could lead to increased patient discontinuation rates, prescriber reluctance, adverse regulatory actions, and reputational damage, posing significant financial risks to investors in Soleno.
See More
Soleno Therapeutics Shareholder Class Action Filed
- Class Action Initiation: A shareholder has filed a securities class action lawsuit against Soleno Therapeutics (NASDAQ: SLNO) on behalf of investors who purchased shares between March 26, 2025, and August 4, 2025, alleging misrepresentations regarding the company's Phase 3 clinical trial for DCCR, which may have led to investor losses.
- Legal Procedure Details: Investors wishing to serve as lead plaintiffs must file necessary documents by May 5, 2026, with the lead plaintiff representing other shareholders in directing the litigation, although non-lead plaintiffs can still share in any recovery.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal’s “Plaintiffs’ Hot List” for its success in litigating hundreds of class actions, showcasing its strong reputation in securities litigation.
- Transparent Fee Structure: All representation in this lawsuit is on a contingency fee basis, meaning shareholders incur no fees or expenses, which reduces the financial burden on investors and encourages more affected shareholders to participate.
See More
Multiple Companies Face Class Action Lawsuits
- Eos Energy Lawsuit: Eos Energy Enterprises is facing allegations for failing to meet production and capacity utilization targets from November 2025 to February 2026, which could severely undermine investor confidence and negatively impact its stock performance.
- Soleno Therapeutics Risks: Soleno Therapeutics is accused of concealing safety concerns in its DCCR clinical trials, potentially exposing patients to greater risks, which may adversely affect product acceptance and commercial viability, leading to potential investor losses.
- Nektar Therapeutics Trial Issues: Nektar Therapeutics is under scrutiny for not adhering to applicable standards in its REZOLVE-AA trial, which could compromise the integrity of trial results and affect future R&D and market strategies, creating uncertainty for shareholders.
- Driven Brands Financial Errors: Driven Brands is accused of financial reporting errors from 2023 to 2026, resulting in misstatements of cash flows and revenues, which could negatively impact its financial health and investor confidence.
See More
Soleno Therapeutics Securities Class Action Reminder
- Lawsuit Background: Hagens Berman reminds investors of the pending securities class action against Soleno Therapeutics (NASDAQ:SLNO), with a lead plaintiff deadline of May 5, 2026, for those who purchased shares between March 26 and November 4, 2025.
- Safety Risk Allegations: The lawsuit alleges that Soleno misrepresented the safety and commercial viability of its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, leading to significant investor losses due to concealed risks.
- Stock Price Plunge: On November 4, 2025, Soleno reported Q3 results, admitting disruptions in DCCR's launch trajectory, resulting in a 27% stock price drop in one day, indicating severe market disappointment regarding the company's future.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to consider the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, thereby aiding the investigation into Soleno's practices.
See More
